Loading the section…

IXHL: financial statements from SEC — TradeAlmanac

IXHL

Incannex Healthcare Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	31/12/2025	30/09/2025	31/03/2025	31/12/2024	30/09/2024
Revenue	—	—	—	—	12,000	74,000
Research and development	321,000	2M	1M	3M	1M	3M
Selling, general and administrative	4M	5M	6M	2M	4M	3M
Operating expenses	4M	7M	7M	5M	5M	6M
Operating income	−4M	−7M	−7M	−5M	−5M	−6M
Pre-tax income	−4M	−7M	−6M	−4M	−6M	−5M
Net income	−4M	−7M	−6M	−4M	−6M	−5M
Earnings per share	−0.35	−0.02	−0.02	−0.20	−0.33	−0.29
Earnings per share, diluted	−0.35	−0.02	−0.02	−0.20	−0.33	−0.29
Weighted average shares	12M	349M	310M	20M	18M	18M
Weighted average shares, diluted	12M	349M	310M	20M	18M	18M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	28/02/2025	31/12/2024	30/09/2024
Cash and equivalents	74M	69M	73M	15M	7M	—	2M	4M
Current assets	80M	75M	78M

Cash flow

Metric	30/09/2025	30/09/2024
Operating cash flow	−9M	−2M
Depreciation and amortisation	66,000	64,000
Share-based compensation	3M	459,000
Capital expenditure	2,000	—
Investing cash flow	−42,000	—
Financing cash flow

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator